Publications and Presentations

News Release | 17 January 2012
Urinary Proteome Analysis enables personalized medicine

Diabetes mellitus affects almost 10% of the European population. The number of patients has increased significantly within the last years and the expenditure on patients with diabetes accounts for 15% of the European health care budget expenditure. Most patients suffer from type 2 diabetes. Furthermore, decreasing age at diagnosis and prolonged duration of diabetes contribute to an increased development of diabetic complications. Diabetic nephropathy is one of the major complications. In progress of disease, glomerular filtration rate reduces gradually over a period of months or years. This eventually leads to end-stage renal disease requiring renal replacement therapy i.e. dialysis and/or kidney transplantation.

PRIORITY is a European research project that started on 1 January 2012 aiming at the early identification of patients at risk for subsequent preventive therapy and analysis of its effects.

Dr Peter Rossing from Steno Diabetes Center near Copenhagen is coordinator of PRIORITY. Other participants are mosaiques diagnostics, Glasgow University, University Hospital Zürich and Hannover Clinical Trial Center.

Urinary proteome analysis is an innovative technology approach having demonstrated its high accuracy and reliability in more than 40 clinical trials so far. After identification of patients at risk, the project aims at showing positive effects of treatment with aldosterone blockade on top of standard therapy.

3280 type 2 diabetic patients will be included in this project. About 20% are at-risk patients and will be assigned to aldosterone blocker. Patients who are classified as being at low risk for progression to diabetic nephropathy will continue to receive usual care. “Our objective is to show the significant benefit the specific therapy provides for affected patients”, says Professor Harald Mischak from mosaiques diagnostics.

 

 

 

Presentations:

DIABETIC KIDNEY DISEASE

C. Delles. Lecture to Renal Trainees atQueenElizabethUniversityHospital,Glasgow,UK, May 2018.

 

MICRO-RNAS IN HYPERTENSION

C. Delles. European Meeting in Hypertension and Cardiovascular Protection,Barcelona,Spain, June 2018.


SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY IABETIC NEPHROPTHY

G. Currie, B. J. Von Scholten, M. Lindhardt, H. Reihnard, P. Jacobsen, W. Mullen, H. H. Parving, H. Mischak, P. Rossing, C. Delles. European Meeting in Hypertension and Cardiovascular Protection,Barcelona,Spain, June 2018.


VASCULAR TISSUE PROTEOMICS AND DETECTION OF CELL TYPE-SPECIFIC CHANGES IN TARGET EXPRESSION

C. Delles, K. Pinel, S. Mary, EJ. Carrick, D. Graham, W. Mullen, SA. Nicklin. 18th International SHR Meeting,Shanghai,China, Sept 2018.

 

PROTEOMIC-BIOSTATISTIC APPROACH IN HYPERTENSION

Christian Delles. Hypertension 2018,Beijing,China, Sept 2018.

 

DIABETIC KIDNEY DISEASE: PREDICTION, PREVENTION AND PRESCRIBING

G. Currie. NAPP Pharmaceuticals primary care training event,Carlisle.UK, Nov 2018.

 

URINARY PROTEOMICS MAY UNMASK THE RENAL POTENTIAL OF THE DPP-4 INHIBITOR LINAGLIPTIN IN PATIENTS WITH DIABETIC KIDNEY DISEASE. (FO041)

H. Mischak. ERA-EDTA 2018,Copenhagen,Denmark, May 2018.

 

PROTEOMICS IN DER PÄDIATRISCHEN NEPHROLOGIE – BEREIT FÜR DEN ROUTINEEINSATZ? (EV1)

H. Mischak. GPN 2018,Hannover,Germany, February/March 2018.

 

CKD: RECENT ADVANCES AND THE UNMET MEDICAL NEED

P. Rossing. Bayer CKD Investigator meeting,Rome,Italy, January 2018.

 

OPTIMAL TREATMENT OF DIABETIC PATIENT WITH ALBUMINURIA - DIABETIC NEPHROPATHY NEW TRENDS

P. Rossing. ERA EDTA 2018,Copenhagen,Denmark, May 2018.

 

PROGNOSIS AND TREATMENT OF DIABETIC NEPHROPATHY: RECENT ADVANCES

P. Rossing. Eli Lilly Global Leaders Meeting,Amsterdam, TheNetherlands, December 2018.

 

HYPERTENSION AND DIABETES 2018

P. Rossing. Post graduate training in nephrology,Skejby,Denmark, 2018.

 

RISK ASSESSMENT -PREDICTION AND TREATMENT RESPONSE

P. Rossing. Danish Society for Pharmacology and Toxicology,Sandbjerg,Denmark, November 2018.


DIABETIC NEPHROPATHY

P Rossing. Novo Nordisk Foundation Steno Centers Day October 2018.

 

PROGNOSIS AND TREATMENT OF DIABETIC NEPHROPATHY: RECENT ADVANCES AND PERSPECTIVES.

P. Rossing. Actualities de Nephrologie 2018, Paris, France, April 2018.

 

NEW PERSPECTIVES IN THERAPEUTICS FOR HYPERTENSION AND DIABETIC KIDNEY DISEASE

P Rossing. Congresso Brasileiro de Endocrinologia et Metabologia, Belo Horizonte, Brazil, August 2018.

 

Posters:

CLINICAL CHARACTERISTICS OF MEN AND WOMEN ATTENDING A SECONDARY CARE DIABETIC NEPHROPATHY SERVICE

GE. Currie, K. Stevens, G. McKay. British Endocrine Society meeting, Glasgow.UK, Nov 2018.

 

DIFFERENTIAL REGULATION OF URINARY PEPTIDES BETWEEN MEN AND WOMEN AT EARLY STAGES OF DIABETIC NEPHROPATHY

C. Delles, BJ. von Scholten, M. Lindhardt, H. Reinhard; PK. Jacobsen, W. Mullen; HH. Parving, H. Mischak, P. Rossing and GE. Currie. British Endocrine Society meeting,Glasgow,UK, Nov 2018.

 

URINARY PROTEOMICS MAY UNMASK THE RENAL POTENTIAL OF THE DIPEPTIDYL PEPTIDASE (DPP)-4 INHIBITOR LINAGLIPTIN IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) (780)

J. Siwy, H. Mischak, T. Klein, M. Von Eynatten. EASD 2018,Berlin,Germany; Oct 2018.

 

URIN-PROTEOMANALYSE ALS MÖGLICHER INDIKATOR FÜR DAS BEHANDLUNGSPOTENTIAL DES DPP-4-INHIBITORS LINAGLIPTIN BEI PATIENTEN MIT DIABETISCHER NIERENERKRANKUNG (P265)

J. Siwy, H. Mischak, P. Zürbig, T. Klein, M. von Eynatten. Hannover, Biberach, Ingelheim. DGfN 2018, Berlin, Germany; Sept 2018.

 

 

Publications:

Currie G, Delles C.

“Precision Medicine and Personalized Medicine in Cardiovascular Disease”

Adv Exp Med Biol. 2018; 1065:589-605. doi: 10.1007/978-3-319-77932-4_36

 

Delles C, Carrick E, Graham D, Nicklin SA.

Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Expert Rev Proteomics. 2018 15(7):581-592. doi: 10.1080/14789450.2018.1493927

 

Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.

”Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes”

Diabet Med. 2018; 35(10):1375-1382. doi: 10.1111/dme.13669

 

Currie GE, von Scholten BJ, Mary S, Flores Guerrero JL, Lindhardt M, Reinhard H, Jacobsen PK, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.

”Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria”

Cardiovasc Diabetol. 2018; 17(1):50. doi: 10.1186/s12933-018-0697-9

 

Currie G, Delles C.

“Blood pressure targets in the elderly”

J Hypertens. 2018; 36(2):234-236. doi: 10.1097/HJH.0000000000001576

 

Delles C, Currie G.

“Sex differences in hypertension and other cardiovascular diseases”

J Hypertens. 2018; 36(4):768-770. doi: 10.1097/HJH.0000000000001655

 

Critselis E, Vlahou A, Stel VS, Morton RL.

”Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion”

Nephrol Dial Transplant. 2018; 33(3):441-449. doi: 10.1093/ndt/gfx068

 

Persson F, Rossing P.

“Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives”

Proteomics Clin Appl. 2019; 11:e1800176. doi: 10.1002/prca.201800176

 

Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

”Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis”

Nephrol Dial Transplant. 2017; 32(12):2079-2089. doi: 10.1093/ndt/gfw337

 

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

”Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker”

Kidney Int Rep. 2017; 2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004

 

Currie G, Delles C.

Healthy Vascular Aging

Hypertension. 2017; 70(2):229-231. doi: 10.1161/HYPERTENSIONAHA.117.09122

 

Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJ, Siwy J, Mullen W, Vlahou A, Mischak H, Vanholder R, Zürbig P, Jankowski J.

”A urinary proteome-based classifier for the early detection of decline in glomerular filtration”

Nephrol Dial Transpl. 2017; 32(9):1510-16. doi: 10.1093/ndt/gfw239

 

Nkuipou-Kenfack E, Zürbig P, Mischak H.

”The long path towards implementation of clinical proteomics: Exemplified based on CKD273”

Proteomics Clin Appl. 2017 May;11(5-6). doi: 10.1002/prca.201600104

 

Currie G, Delles C.

”The Future of "Omics" in Hypertension”

Can J Cardiol. 2017; 33(5):601-610. doi: 10.1016/j.cjca.2016.11.023

 

Magalhães P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Švec-Billá D, Rychlík I, Rroji M, Restivo A, Capasso G, Bob F, Schiller A, Ortiz A, Perez-Gomez MV, Cannata P, Sanchez-Niño MD, Naumovic R, Brkovic V, Polenakovic M, Mullen W, Vlahou A, Zürbig P, Pape L, Ferrario F, Denis C, Spasovski G, Mischak H, Schanstra JP.

”Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?”

Sci Rep. 2017; 7(1):16915. doi: 10.1038/s41598-017-17083-w

 

Pontillo C,Mischak H.

”Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease”

Clin Kidney J. 2017; 10(2):192-201. doi: 10.1093/ckj/sfx002

 

Lindhardt M, Persson F, Zürbig P, Stalmach A, Mischak H, de Zeeuw D, Lambers Heerspink H, Klein R, Orchard T, Porta M, Fuller J, Bilous R, Chaturvedi N, Parving HH, Rossing P.

”Urinary Proteomics Predict Onset of Microalbuminuria in Normoalbuminuric Type 2 Diabetic Patients, a sub-study of the DIRECT-Protect 2 Study”

Nephrol Dial Transpl, 2017; 32(11): 1866-73. doi:10.1093/ndt/gfw292

 

Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

”Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis”

Nephrol Dial Transplant. 2017; 32(12):2079-2089. doi: 10.1093/ndt/gfw337

 

Magalhães P, Mischak H, Zürbig P.

”Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases”

Curr Opin Nephrol Hypertens. 2016 ; 25(6):494-501. doi: 10.1097/MNH.0000000000000278

 

Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggenenti PL, Rychlik I, Spasovski G, Rossing P. 

”Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial”

BMJ Open. 2016; 6(3):e010310. doi: 10.1136/bmjopen-2015-010310

 

Small HY, Currie GE, Delles C.

”Prostasin, proteases, and preeclampsia”

J Hypertens. 2016; 34(2):193-5. doi: 10.1097/HJH.0000000000000828

 

Currie G, Delles C.

”Urinary Proteomics for Diagnosis and Monitoring of Diabetic Nephropathy”

Curr Diab Rep. 2016; 16(11):104. doi: 10.1007/s11892-016-0798-3

 

Pena MJ, Mischak H, Heerspink HJ.

”Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease”

Diabetologia. 2016; 59(9):1819-31. doi: 10.1007/s00125-016-4001-9

 

Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, van den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB.

“Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis”

BMC Nephrol. 2016; 17(1):127. doi: 10.1186/s12882-016-0337-0

 

Currie G, Delles C.

“Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients”

Curr Hypertens Rep. 2016; 18(7):54. doi: 10.1007/s11906-016-0661-6

 

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

”Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides”

J Am Soc Nephrol. 2015; 26(8):1999-2010. doi: 10.1681/ASN.2014050423

 

Mischak H, Delles C, Vlahou A, Vanholder R.

”Proteomic biomarkers in kidney disease: issues in development and implementation”

Nat Rev Nephrol. 2015; 11(4):221-32. doi: 10.1038/nrneph.2014.247

 

Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J.

”Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy”

Nephrol Dial Transpl 2014; 29(8):1563-70. doi: 10.1093/ndt/gfu039

 

Currie G, McKay G and Delles C.

"Biomarkers in diabetic nephropathy: Present and future"

World J Diabetes. 2014; 5(6):763-76. doi: 10.4239/wjd.v5.i6.763

 

Currie G, Delles C.

”Proteinuria and its relation to cardiovascular disease”

Int J Nephrol Renovasc Dis. 2013; 7:13-24. doi: 10.2147/IJNRD.S40522

 

ShoppingASEhandelASErhvervIndexDKServiceIndexDK